课题基金 / 基金详情

Task B21: Drug Development for Enterobacteriaciae

Task B21: Drug Development for Enterobacteriaciae
任务 B21:肠杆菌药物开发
批准号:
10392655
负责人:
MARY BASTIDA
金额:
$14.31万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-02 至 2021-09-30

项目摘要

项目成果

MARY BASTIDA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION. TASK ORDER 03 OBLIGATED IN THE AMOUNT OF $136
  • 批准号:
    10710585
  • 项目类别:
  • 资助金额:
    $16.57万
  • 财政年份:
    2021
  • 负责人:
    MARY BASTIDA
  • 依托单位:
IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION. FIRST TASK ORDER 01 OBLIGATED IN THE AMOUNT O
  • 批准号:
    10505766
  • 项目类别:
  • 资助金额:
    $8.97万
  • 财政年份:
    2021
  • 负责人:
    MARY BASTIDA
  • 依托单位:
Task C04: Stability testing of an antiparasitic therapeutic
  • 批准号:
    10329791
  • 项目类别:
  • 资助金额:
    $2.12万
  • 财政年份:
    2019
  • 负责人:
    MARY BASTIDA
  • 依托单位:
Task C04: Stability testing of an antiparasitic therapeutic
  • 批准号:
    10551084
  • 项目类别:
  • 资助金额:
    $2.17万
  • 财政年份:
    2019
  • 负责人:
    MARY BASTIDA
  • 依托单位:
海外基金